Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Asset Resilience Ratio
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS asset resilience ratio. Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has an Asset Resilience Ratio of 0.62% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read GENIL total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2022–2024)
Asset resilience ratio of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2022 to 2024. This chart shows how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's Asset Resilience Ratio has changed over time. See GENIL free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Gen Ilac ve Saglik Urunleri Sanayi ve Ti balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0% |
| Short-term Investments | TL106.64 Million | 0.62% |
| Total Liquid Assets | TL106.64 Million | 0.62% |
Asset Resilience Insights
- Limited Liquidity: Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS maintains only 0.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Industry Peers by Asset Resilience Ratio
Compare Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Asset Resilience Ratio by Year (2022–2024)
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.75% | TL92.52 Million ≈ $2.07 Million |
TL12.31 Billion ≈ $275.73 Million |
-0.08pp |
| 2023-12-31 | 0.83% | TL92.90 Million ≈ $2.08 Million |
TL11.13 Billion ≈ $249.39 Million |
-10.52pp |
| 2022-12-31 | 11.35% | TL418.01 Million ≈ $9.36 Million |
TL3.68 Billion ≈ $82.48 Million |
-- |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more